XXXX -Induced Changes in Anterior Chamber Angle and @entity3193 .

@entity1 @entity2704 @entity1771 @entity3193 @entity158
PURPOSE: To investigate the acute effects of @entity1771 on the anterior chamber angle (ACA) and @entity3193 in @entity1 with @entity2704 . METHODS: This prospective study included 15 eyes of 15 @entity1 with @entity2704 who have been scheduled to start @entity1771 therapy. All @entity1 underwent complete ophthalmic examination including measurement of the ACA and @entity3193 using a spectral domain optical coherence tomography device (Optovue Inc.) and refractive status evaluation with an autorefractokeratometer (KR-8100; Topcon) at the baseline and 1 week after starting therapy. The @entity1 were asked to report any @entity158 or discomfort in their eyes during therapy at the follow-up visit. RESULTS: None of the @entity1 experienced @entity158 or discomfort in their eyes. The mean ACA significantly decreased at the first week of the therapy compared with the baseline levels (40.34  7.06   and 36.89  6.87  , respectively) (P=0.001). However, the mean @entity3193 increased from 277.33  95.60  m at the baseline to 323.40  84.50  m at the first week (P=0.01). There was a nonsignificant increase in the mean refractive error (from -0.25  0.54 diopter [D] at the baseline to -0.38  0.49 D after 1 week) (P=0.06). CONCLUSIONS: @entity1771 can acutely decrease the ACA and increase the @entity3193 . Because these effects may be asymptomatic, @entity1 with @entity2704 who start this therapy should be warned to be closely followed up by an ophthalmologist.
